248 related articles for article (PubMed ID: 37444135)
1. Soft Tissue Ewing Sarcoma Cell Drug Resistance Revisited: A Systems Biology Approach.
Asfa S; Toy HI; Arshinchi Bonab R; Chrousos GP; Pavlopoulou A; Geronikolou SA
Int J Environ Res Public Health; 2023 Jul; 20(13):. PubMed ID: 37444135
[TBL] [Abstract][Full Text] [Related]
2. Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.
Kennedy AL; Vallurupalli M; Chen L; Crompton B; Cowley G; Vazquez F; Weir BA; Tsherniak A; Parasuraman S; Kim S; Alexe G; Stegmaier K
Oncotarget; 2015 Oct; 6(30):30178-93. PubMed ID: 26337082
[TBL] [Abstract][Full Text] [Related]
3. Cancer Stem Cells and Chemoresistance in Ewing Sarcoma.
Dos Santos RP; Roesler R; Gregianin L; Brunetto AT; da Cunha Jaeger M; Lunardi Brunetto A; de Farias CB
Curr Stem Cell Res Ther; 2023; 18(7):926-936. PubMed ID: 35761483
[TBL] [Abstract][Full Text] [Related]
4. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
5. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
6. Poison-Exon Inclusion in DHX9 Reduces Its Expression and Sensitizes Ewing Sarcoma Cells to Chemotherapeutic Treatment.
Palombo R; Verdile V; Paronetto MP
Cells; 2020 Jan; 9(2):. PubMed ID: 32023846
[TBL] [Abstract][Full Text] [Related]
7. RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma.
Roundhill EA; Chicon-Bosch M; Jeys L; Parry M; Rankin KS; Droop A; Burchill SA
Cell Oncol (Dordr); 2021 Oct; 44(5):1065-1085. PubMed ID: 34403115
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
Yuan B; Ji W; Xia H; Li J
Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
[TBL] [Abstract][Full Text] [Related]
10. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
[TBL] [Abstract][Full Text] [Related]
11. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.
Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD
Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901
[TBL] [Abstract][Full Text] [Related]
12. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
13. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
14. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
15. Ewing sarcoma and Ewing-like tumors.
Sbaraglia M; Righi A; Gambarotti M; Dei Tos AP
Virchows Arch; 2020 Jan; 476(1):109-119. PubMed ID: 31802230
[TBL] [Abstract][Full Text] [Related]
16. USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma.
Henrich IC; Young R; Quick L; Oliveira AM; Chou MM
Mol Cancer Res; 2018 Dec; 16(12):1834-1843. PubMed ID: 30131449
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.
Huertas-Martínez J; Court F; Rello-Varona S; Herrero-Martín D; Almacellas-Rabaiget O; Sáinz-Jaspeado M; Garcia-Monclús S; Lagares-Tena L; Buj R; Hontecillas-Prieto L; Sastre A; Azorin D; Sanjuan X; López-Alemany R; Moran S; Roma J; Gallego S; Mora J; García Del Muro X; Giangrande PH; Peinado MA; Alonso J; de Alava E; Monk D; Esteller M; Tirado OM
Cancer Lett; 2017 Feb; 386():196-207. PubMed ID: 27894957
[TBL] [Abstract][Full Text] [Related]
19. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.
Pishas KI; Drenberg CD; Taslim C; Theisen ER; Johnson KM; Saund RS; Pop IL; Crompton BD; Lawlor ER; Tirode F; Mora J; Delattre O; Beckerle MC; Callen DF; Sharma S; Lessnick SL
Mol Cancer Ther; 2018 Sep; 17(9):1902-1916. PubMed ID: 29997151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
